Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for migraine
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. Importance: Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine. Objective: To assess the efficacy of fremanezumab compared with placebo for prevention of episodic migraine with a monthly dosing regimen or a single higher dose. Design and Setting: Randomized, double-blind, placebo-controlled (...) , parallel-group trial conducted at 123 sites in 9 countries from March 23, 2016 (first patient randomized), to April 10, 2017, consisting of a screening visit, 28-day pretreatment period, 12-week treatment period, and final evaluation at week 12. Participants: Study participants were aged 18 to 70 years with episodic migraine (6-14 headache days, with at least 4 migraine days, during 28-day pretreatment period). Patients who had previous treatment failure with 2 classes of migraine-preventive medication
Acupuncture shows promise for preventing episodic migraines NIHR DC | Signal - Acupuncture shows promise for preventing episodic migraines Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Acupuncture shows promise for preventing episodic migraines Published on 18 October 2016 Acupuncture was about as effective as long term medication in reducing the number of migraines. There were fewer adverse events amongst people receiving acupuncture (16-17%) compared to drug treatment (34 (...) %). Migraines affect around one in seven people in the UK. Their unpleasant symptoms last between four and 72 hours and can impact on people’s ability to do everyday tasks, such as going to work. This systematic review looked at acupuncture delivered at least once a week for up to six sessions, similar to the NICE recommendation of up to ten sessions over five to eight - weeks. Acupuncture may be a preventative treatment option for those willing to have it but NHS provision of acupuncture is variable
Common migraine prevention treatments found to be equally effective NIHR DC | Signal - Common migraine prevention treatments found to be equally effective Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Common migraine prevention treatments found to be equally effective Published on 24 September 2015 This review found that the main drugs used for preventing migraine were all effective compared with placebo or dummy treatment. The results were less clear cut when comparing (...) drugs directly against each other as there were fewer trials. This review highlights the range of drugs used to prevent migraines, reflecting the number of possible treatments available. The review’s conclusions suggest that the prescriber could be guided by individual patient characteristics, including preferences, pre-existing conditions and potential side effects. This review confirms and strengthens NICE guidance in this area. Why was this study needed? Migraines affect around 15% of people
“Triptans” can relieve migraines in children and adolescents NIHR DC | Signal - “Triptans” can relieve migraines in children and adolescents Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal “Triptans” can relieve migraines in children and adolescents Published on 13 September 2016 Triptans, a migraine medication, relieve migraine headache completely within two hours compared to placebo. Ibuprofen was also effective but less well studied. This review was also reassuring (...) in that any side effects of treatment were mild. Most evidence identified in this Cochrane review was for sumatriptan, a commonly prescribed treatment for adults, compared to placebo or dummy pills. A few studies examined other triptans or other painkillers, such as ibuprofen or paracetamol against placebo in children and adults. The findings support current guideline recommendations to prescribe nasal triptans for migraine in adolescents. Only nasal preparations are currently licensed for adolescents
Efficacy of combination of Viola odorata, Rosa damascena and Coriandrum sativum in prevention of migraine attacks: a randomized, double blind, placebo-controlled clinical trial Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir March 2018, Volume: 10, Issue: 3, Pages: 6430-6438, DOI: http://dx.doi.org/10.19082/6430 Corresponding author: Assistant Professor Dr. Haleh Tajadini. Kerman University of Medical Sciences, Kerman, Iran. Tel: +98.9131972312, Fax: +98.3433122023, Email (...) , the use is non-commercial and no modifications or adaptations are made. Page 6430 Efficacy of combination of Viola odorata, Rosa damascena and Coriandrum sativum in prevention of migraine attacks: a randomized, double blind, placebo- controlled clinical trial Mohadese Kamali 1, 2 , Rostam Seifadini 3 , Hoda Kamali 3 , Mitra Mehrabani 4 , Yunes Jahani 5, 6 , Haleh Tajadini 2, 7 1 MD, Persian Medicine Student, Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran 2 Department
Migraine. Migraine is a chronic paroxysmal neurological disorder characterised by multiphase attacks of head pain and a myriad of neurological symptoms. The underlying genetic and biological underpinnings and neural networks involved are coming sharply into focus. This progress in the fundamental understanding of migraine has led to novel, mechanism-based and disease-specific therapeutics. In this Seminar, the clinical features and neurobiology of migraine are reviewed, evidence to support
Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir February 2018, Volume: 10, Issue: 2, Pages: 6279-6285, DOI: http://dx.doi.org/10.19082/6279 Corresponding author: Associate Professor Dr. Babak Soltani, Kashan University of Medical Sciences, Kashan, Iran. Tel: +98.9123887085, Fax: +98.3155548900, Email: email@example.com Received: February 06, 2017, Accepted (...) or adaptations are made. Page 6279 Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial Ahmad Talebian 1,2 , Babak Soltani 2,3 , Hamid Reza Banafshe 4 , Gholam Abbas Moosavi 5 , Motahhareh Talebian 6 , Siamak Soltani 7 1 M.D., Pediatric Neurologist, Professor, Department of Pediatrics, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran 2 Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran 3 M.D
Pharmacological management of migraine SIGN 155 • Pharmacological management of migraine A national clinical guideline February 2018 Evidence www.healthcareimprovementscotland.org Edinburgh Office | Gyle Square |1 South Gyle Crescent | Edinburgh | EH12 9EB Telephone 0131 623 4300 Fax 0131 623 4299 Glasgow Office | Delta House | 50 West Nile Street | Glasgow | G1 2NP Telephone 0141 225 6999 Fax 0141 248 3776 The Healthcare Environment Inspectorate, the Scottish Health Council, the Scottish (...) management of migraine A national clinical guideline February 2018Scottish Intercollegiate Guidelines Network Gyle Square, 1 South Gyle Crescent Edinburgh EH12 9EB www.sign.ac.uk First published February 2018 ISBN 978 1 909103 62 7 Citation text Scottish Intercollegiate Guidelines Network (SIGN). Pharmacological management of migraine. Edinburgh: SIGN; 2018. (SIGN publication no. 155). [February 2018]. Available from URL: http://www.sign.ac.uk SIGN consents to the photocopying of this guideline
Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. OBJECTIVE: To examine the risks of myocardial infarction, stroke (ischaemic and haemorrhagic), peripheral artery disease, venous thromboembolism, atrial fibrillation or atrial flutter, and heart failure in patients with migraine and in a general population comparison cohort. DESIGN: Nationwide, population based cohort study. SETTING: All Danish hospitals and hospital outpatient clinics from 1995 to 2013 (...) . PARTICIPANTS: 51 032 patients with migraine and 510 320 people from the general population matched on age, sex, and calendar year. MAIN OUTCOME MEASURES: Comorbidity adjusted hazard ratios of cardiovascular outcomes based on Cox regression analysis. RESULTS: Higher absolute risks were observed among patients with incident migraine than in the general population across most outcomes and follow-up periods. After 19 years of follow-up, the cumulative incidences per 1000 people for the migraine cohort compared
Botulinum Toxin A for Chronic Migraines: Clinical Effectiveness Botulinum Toxin A for Chronic Migraines: Clinical Effectiveness | CADTH.ca Find the information you need Botulinum Toxin A for Chronic Migraines: Clinical Effectiveness Botulinum Toxin A for Chronic Migraines: Clinical Effectiveness Published on: January 3, 2018 Project Number: RB1176-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of botulinum (...) toxin A for patients with chronic migraines? What is the clinical effectiveness of botulinum toxin A plus opioid derivatives for patients with chronic migraines? Key Message Two systematic reviews, six randomized controlled trials, and two non-randomized studies were identified regarding the clinical effectiveness of botulinum toxin A for patients with chronic migraines. Tags headache disorders, nervous system, botulinum toxins, type a, migraine disorders, Botox Files Rapid Response Summary
Migraine headache in children Migraine headache in children - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Migraine headache in children Last reviewed: August 2018 Last updated: May 2018 Important updates European Medicines Agency (EMA) strengthens measures to avoid use of valproate medicines in pregnancy In March 2018, the EMA announced stronger measures aimed at avoiding the exposure of babies to valproate (...) medicines in the womb. Under the new restrictions, valproate medicines are contraindicated for migraine prophylaxis during pregnancy due to the high risk of congenital malformations and developmental problems in the child. In addition, valproate medicines must not be used in female patients of childbearing age, unless there is a pregnancy prevention programme in place that includes: An assessment of the patient’s potential for becoming pregnant Pregnancy tests before starting and during treatment
Migraine headache in adults Migraine headache in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Migraine headache in adults Last reviewed: August 2018 Last updated: August 2018 Important updates European Medicines Agency (EMA) strengthens measures to avoid use of valproate medicines in pregnancy In March 2018, the EMA announced stronger measures aimed at avoiding the exposure of babies to valproate medicines (...) in the womb. Under the new restrictions, valproate medicines are contraindicated for migraine prophylaxis during pregnancy due to the high risk of congenital malformations and developmental problems in the child. In addition, valproate medicines must not be used in female patients of childbearing potential unless there is a pregnancy prevention programme in place that includes the following: An assessment of the patient’s potential for becoming pregnant Pregnancy tests before starting (and during
Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial 29191325 2017 12 05 2017 12 05 1558-3597 70 22 2017 Dec 05 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial. 2766-2774 S0735-1097(17)41045-X 10.1016/j.jacc.2017.09.1105 Migraine is a prevalent and disabling disorder. Patent foramen ovale (PFO) has been associated with migraine, but its role (...) in the disorder remains poorly understood. This study examined the efficacy of percutaneous PFO closure as a therapy for migraine with or without aura. The PREMIUM (Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management) was a double-blind study investigating migraine characteristics over 1 year in subjects randomized to medical therapy with a sham procedure (right heart catheterization) versus
Fremanezumab for the Preventive Treatment of Chronic Migraine. BACKGROUND: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment for migraine. We compared two fremanezumab dose regimens with placebo for the prevention of chronic migraine. METHODS: In this phase 3 trial, we randomly assigned patients with chronic migraine (defined as headache of any duration or severity on ≥15 days per month and migraine (...) of at least a moderate level or days in which acute migraine-specific medication [triptans or ergots] was used to treat a headache of any severity or duration) per month during the 12 weeks after the first dose. RESULTS: Of 1130 patients enrolled, 376 were randomly assigned to fremanezumab quarterly, 379 to fremanezumab monthly, and 375 to placebo. The mean number of baseline headache days (as defined above) per month was 13.2, 12.8, and 13.3, respectively. The least-squares mean (±SE) reduction
A Controlled Trial of Erenumab for Episodic Migraine. BACKGROUND: We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine. METHODS: We randomly assigned patients to receive a subcutaneous injection of either erenumab, at a dose of 70 mg or 140 mg, or placebo monthly for 6 months. The primary end point was the change from baseline to months 4 through 6 in the mean number of migraine days per month (...) . Secondary end points were a 50% or greater reduction in mean migraine days per month, change in the number of days of use of acute migraine-specific medication, and change in scores on the physical-impairment and everyday-activities domains of the Migraine Physical Function Impact Diary (scale transformed to 0 to 100, with higher scores representing greater migraine burden on functioning). RESULTS: A total of 955 patients underwent randomization: 317 were assigned to the 70-mg erenumab group, 319
Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine 29046364 2017 10 19 2017 11 14 1526-632X 89 20 2017 Nov 14 Neurology Neurology Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. 2075-2082 10.1212/WNL.0000000000004642 To determine outcomes among patients with migraine in the emergency department (ED) who receive IV hydromorphone vs IV prochlorperazine + diphenhydramine. This study was conducted in 2 EDs (...) in New York City. Patients who met international criteria for migraine were eligible for participation if they had not used an opioid within the previous month. Clinicians, participants, investigators, and research personnel were blinded to treatment. Patients were randomized in blocks of 4. Participants received hydromorphone 1 mg or prochlorperazine 10 mg + diphenhydramine 25 mg. Diphenhydramine was administered to prevent akathisia, a common side effect of IV prochlorperazine. The primary outcome
Galcanezumab for the prophylaxis of episodic and chronic migraine Galcanezumab for the prophylaxis of episodic and chronic migraine ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Galcanezumab for the prophylaxis of episodic and chronic migraine October 2017 Technology Description: Galcanezumab is being developed as one of a class of specific anti-migraine preventative drugs. By stopping a very specific protein in the brain and nervous system, galcanezumab (...) reduces migraine attacks. Additionally as it is given once-a-month as treatment, it avoids the need to take numerous pills per day. If marketed, galcanezumab may be more preferable to current treatment options for episodic migraine and chronic migraine prevention. Specialty You may also be interested in: Apr 2015 Specialty: Apr 2015 Specialty: Apr 2015 Specialty: Please answer these 2 questions to proceed to your free download Where are you based? England Wales, Scotland, N.Ireland Other country (non
Migraines and Myocardial Infarction in Women "Migraines and Myocardial Infarction in Women" by Haley Moak > > > > Title Author Date of Graduation Summer 8-12-2017 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Heart disease is the number 1 cause of death for U.S. women, myocardial infarction (MI) included. It has been established that ischemic stroke has a positive correlation with those who experience migraines (...) , but there were no definitive studies saying that migraines cause all other cardiovascular related diseases, even though there is a common consensus that migraines are a vascular phenomenon. This systematic review focuses on the correlation between migraines and myocardial infarction particularly in women. Methods: An exhaustive search of available medical literature was conducted using MEDLINE-Ovid, Web of Science, and CINAHL databases. The following terms were searched as keywords: migraine
Prophylactic use of Immediate Release Melatonin for Decreasing Occurrence, Severity, and Duration of Migraines in the Adult Population "Prophylactic use of Immediate Release Melatonin for Decreasing Occurre" by Robert Barnes > > > > Title Author Date of Graduation Summer 8-11-2017 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Abstract: Background: Research has begun to uncover the likely role of melatonin in primary headache (...) disorders such as migraine. The pineal gland produces the hormone melatonin and is largely influenced by environmental stimuli.Migraines often have environmental triggers with research starting to show lower levels of circulating melatonin found in migraineurs. Melatonin is an inexpensive, easily procured, and natural hormone with a minimal side effect profile compared to current pharmacologic migraine treatments. It is thought that migraine treatment with melatonin can decrease migraine occurrence
Migraine Prevention Using Different Frequencies of Transcutaneous Occipital Nerve Stimulation: A Randomized Controlled Trial 28428093 2017 04 21 2017 07 31 1528-8447 18 8 2017 Aug The journal of pain : official journal of the American Pain Society J Pain Migraine Prevention Using Different Frequencies of Transcutaneous Occipital Nerve Stimulation: A Randomized Controlled Trial. 1006-1015 S1526-5900(17)30550-3 10.1016/j.jpain.2017.03.012 This study's objective was to evaluate the efficacy (...) and tolerability of transcutaneous occipital nerve stimulation (tONS) in patients with migraine, and to explore whether different tONS frequencies influenced treatment effectiveness. This was a randomized, controlled trial of tONS for prevention of migraine. Patients were randomized to 1 of 5 therapeutic groups before treatment for 1 month. Groups A through C received tONS at different frequencies (2 Hz, 100 Hz, and 2/100 Hz), group D underwent sham tONS intervention, and group E received topiramate orally